Age-Related Macular Degeneration

Iveric Bio has submitted the first part of a new drug application to the FDA for a rolling review of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration.

Before the 2022 American Academy of Ophthalmology meeting, Verana Health, the technology, data and analytics partner for the Academy’s IRIS Registry, shared its 2021 IRIS Registry Industry Report.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Michael Nathan Cohen, MD, discusses phase 1 data investigating JNJ-81201887 gene therapy from Janssen for the treatment of geographic atrophy.

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.

While most Americans value their eyesight, less than half surveyed are aware of age-related macular degeneration, a leading cause of blindness in older adults, according to a Bausch + Lomb press release.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Tom Ruggia, president and CEO of Samsara Vision, discusses the ongoing CONCERTO trial investigating the Sing IMT as well as the device’s commercialization around the world.

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works.

The first patient has been dosed in the phase 2 DAVIO 2 clinical trial assessing EYP-1901 for the treatment of wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Allison W. Shuren, JD, MSN.

Regulatory approval of a novel artificial intelligence-based tool that provides precise measurement of retinal fluid may introduce major paradigm changes in the monitoring of patients with neovascular age-related macular degeneration.